Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 6 (June)

1. Drug release from pH-responsive thermogelling pentablock copolymers.
   J Biomed Mater Res A, 81(2): 326-33. [Abstract] [Full-text]
2. Synthesis, characterization, and in vitro activity of antibiotic releasing polyurethanes to prevent bacterial resistance.
   J Biomed Mater Res A, 81(2): 287-98. [Abstract] [Full-text]
3. Paclitaxel-loaded composite fibers: microstructure and emulsion stability.
   J Biomed Mater Res A, 81(2): 427-36. [Abstract] [Full-text]
4. Fabrication and characterization of a novel composite PNIPAAm hydrogel for controlled drug release.
   J Biomed Mater Res A, 81(2): 418-26. [Abstract] [Full-text]
5. Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study.
   Thorac Cardiovasc Surg, 55(4): 233-8. [Abstract] [Full-text]
6. Radiochemotherapy of esophageal cancer.
   J Thorac Oncol, 2(6): 553-68. [Abstract] [Full-text]
7. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
   J Thorac Oncol, 2(6): 537-43. [Abstract] [Full-text]
8. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
   J Thorac Oncol, 2(6): 526-30. [Abstract] [Full-text]
9. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
   J Thorac Oncol, 2(6): 520-5. [Abstract] [Full-text]
10. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6.
    J Thorac Oncol, 2(6): 494-8. [Abstract] [Full-text]
11. Electronic prescribing systems in pediatrics: the rationale and functionality requirements.
    Pediatrics, 119(6): 1229-31. [Abstract] [Full-text]
12. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Ophthalmology, 114(6): 1179-85. [Abstract] [Full-text]
13. Thrombolytic therapy vs primary percutaneous intervention after ventricular fibrillation cardiac arrest due to acute ST-segment elevation myocardial infarction and its effect on outcome.
    Am J Emerg Med, 25(5): 545-50. [Abstract] [Full-text]
14. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management.
    Pediatrics, 119(6): e1371-83. [Abstract] [Full-text]
15. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study.
    J Vasc Surg, 45(6): 1212-6. [Abstract] [Full-text]
16. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Ophthalmology, 114(6): 1170-8. [Abstract] [Full-text]
17. High sensitive C-reactive protein and interleukin 6 are not related to neointimal hyperplasia in paclitaxel eluting stents or bare metal stents. An intravascular ultrasound study.
    Int J Cardiol, 119(1): 114-6. [Abstract] [Full-text]
18. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
    Int J Radiat Oncol Biol Phys, 68(3): 873-82. [Abstract] [Full-text]
19. Confocal microscopy for the elucidation of mass transport mechanisms involved in protein release from lipid-based matrices.
    Pharm Res, 24(7): 1325-35. [Abstract] [Full-text]
20. Transdermal delivery of cytochrome C--A 12.4 kDa protein--across intact skin by constant-current iontophoresis.
    Pharm Res, 24(7): 1360-8. [Abstract] [Full-text]
21. Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer.
    Pharm Res, 24(7): 1396-401. [Abstract] [Full-text]
22. Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats.
    Pharm Res, 24(7): 1389-95. [Abstract] [Full-text]
23. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
    Int J Radiat Oncol Biol Phys, 68(3): 779-85. [Abstract] [Full-text]
24. Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration.
    Pharm Res, 24(7): 1381-8. [Abstract] [Full-text]
25. Coating formulations for microneedles.
    Pharm Res, 24(7): 1369-80. [Abstract] [Full-text]
26. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.
    Int J Radiat Oncol Biol Phys, 68(3): 794-800. [Abstract] [Full-text]
27. Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.
    Int J Radiat Oncol Biol Phys, 68(3): 817-22. [Abstract] [Full-text]
28. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
    Int J Radiat Oncol Biol Phys, 68(3): 823-9. [Abstract] [Full-text]
29. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
    Int J Radiat Oncol Biol Phys, 68(3): 809-16. [Abstract] [Full-text]
30. Bioidentical hormones for menopausal hormone therapy: variation on a theme.
    J Gen Intern Med, 22(7): 1030-4. [Abstract] [Full-text]
31. Aminolevulinic acid 585 nm pulsed dye laser photodynamic treatment of laryngeal keratosis with atypia.
    Otolaryngol Head Neck Surg, 136(6): 882-7. [Abstract] [Full-text]
32. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy.
    Hepatology, 45(6): 1382-9. [Abstract] [Full-text]
33. Results of primary percutaneous coronary intervention in a consecutive group of patients with acute ST elevation myocardial infarction at a tertiary Australian centre.
    Intern Med J, 37(7): 464-71. [Abstract] [Full-text]
34. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone.
    J Gen Intern Med, 22(7): 1003-6. [Abstract] [Full-text]
35. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
    Am J Clin Oncol, 30(3): 297-302. [Abstract] [Full-text]
36. Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
    Am J Clin Oncol, 30(3): 278-82. [Abstract] [Full-text]
37. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
    Am J Clin Oncol, 30(3): 252-7. [Abstract] [Full-text]
38. Acute ventricular and aortic thrombosis post chemotherapy.
    Br J Radiol, 80(952): e75-7. [Abstract] [Full-text]
39. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study.
    J Clin Endocrinol Metab, 92(6): 2074-9. [Abstract] [Full-text]
40. Effects of testosterone treatment on endometrial proliferation in postmenopausal women.
    J Clin Endocrinol Metab, 92(6): 2169-75. [Abstract] [Full-text]
41. Her signaling in pancreatic cancer.
    Expert Opin Biol Ther, 7(6): 823-9. [Abstract] [Full-text]
42. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system.
    Endocr Rev, 28(4): 387-439. [Abstract] [Full-text]
43. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.
    Lancet, 369(9577): 1929-37. [Abstract] [Full-text]
44. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    J Clin Oncol, 25(17): 2360-8. [Abstract] [Full-text]
45. Interactions between U-937 human macrophages and poly(propyleneimine) dendrimers.
    J Control Release, 120(1): 51-9. [Abstract] [Full-text]
46. Gelatin microspheres encapsulated with a nonpeptide angiogenic agent, ginsenoside Rg1, for intramyocardial injection in a rat model with infarcted myocardium.
    J Control Release, 120(1): 27-34. [Abstract] [Full-text]
47. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo.
    J Control Release, 120(1): 41-50. [Abstract] [Full-text]
48. Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery.
    J Control Release, 120(1): 11-7. [Abstract] [Full-text]
49. Biodegradable elastomeric scaffolds with basic fibroblast growth factor release.
    J Control Release, 120(1): 70-8. [Abstract] [Full-text]
50. Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo.
    J Control Release, 120(1): 95-103. [Abstract] [Full-text]
51. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody.
    J Control Release, 120(1): 18-26. [Abstract] [Full-text]
52. Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice.
    Leuk Res, 31(8): 1131-4. [Abstract] [Full-text]
53. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
    Leuk Res, 31(8): 1069-75. [Abstract] [Full-text]
54. Morbidity reduction in critically ill trauma patients through use of a computerized insulin infusion protocol: a preliminary study.
    J Trauma, 62(6): 1370-5; discussion 1375-6. [Abstract] [Full-text]
55. Serum B-type natriuretic peptide: a marker of fluid resuscitation after injury?
    J Trauma, 62(6): 1346-50; discussion 1350-1. [Abstract] [Full-text]
56. Utilization of a computerized intravenous insulin infusion program to control blood glucose in the intensive care unit.
    Diabetes Technol Ther, 9(3): 232-40. [Abstract] [Full-text]
57. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
    Pediatr Blood Cancer, 49(2): 196-8. [Abstract] [Full-text]
58. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
    Pediatr Blood Cancer, 49(2): 190-5. [Abstract] [Full-text]
59. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Pediatr Blood Cancer, 49(2): 127-32. [Abstract] [Full-text]
60. Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 49(2): 198-203. [Abstract] [Full-text]
61. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Oncogene, 26(28): 4071-83. [Abstract] [Full-text]
62. Flow rate, syringe size and architecture are critical to start-up performance of syringe pumps.
    Eur J Anaesthesiol, 24(7): 602-8. [Abstract] [Full-text]
63. Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study.
    Cancer Chemother Pharmacol, 60(3): 365-73. [Abstract] [Full-text]
64. O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
    Cancer Chemother Pharmacol, 60(3): 415-21. [Abstract] [Full-text]
65. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Cancer Chemother Pharmacol, 60(3): 321-8. [Abstract] [Full-text]
66. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 60(3): 383-9. [Abstract] [Full-text]
67. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 60(3): 351-6. [Abstract] [Full-text]
68. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Cancer Chemother Pharmacol, 60(3): 399-406. [Abstract] [Full-text]
69. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
    Invest New Drugs, 25(4): 351-5. [Abstract] [Full-text]
70. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
    Invest New Drugs, 25(4): 335-41. [Abstract] [Full-text]
71. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
    Invest New Drugs, 25(4): 385-90. [Abstract] [Full-text]
72. Controlled loading and release of a model drug from polypeptide multilayer nanofilms.
    Nanomedicine, 3(2): 154-60. [Abstract] [Full-text]
73. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides.
    Nanomedicine, 3(2): 132-7. [Abstract] [Full-text]
74. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers.
    Nanomedicine, 3(2): 120-7. [Abstract] [Full-text]
75. Interstitial photodynamic therapy of the canine prostate using intra-arterial administration of photosensitizer and computerized pulsed light delivery.
    J Urol, 178(1): 308-13. [Abstract] [Full-text]
76. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles.
    Nanomedicine, 3(2): 161-7. [Abstract] [Full-text]
77. Polybutylcyanoacrylate nanoparticles as novel vectors in cancer gene therapy.
    Nanomedicine, 3(2): 144-53. [Abstract] [Full-text]
78. Evidence-based emergency medicine/critically appraised topic. Thrombolytic therapy for submassive pulmonary embolism?
    Ann Emerg Med, 50(1): 78-84. [Abstract] [Full-text]
79. Nanotechnology platforms and physiological challenges for cancer therapeutics.
    Nanomedicine, 3(2): 103-10. [Abstract] [Full-text]
80. Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.
    J Neurol Neurosurg Psychiatry, 78(7): 685-9. [Abstract] [Full-text]
81. The case for routine use of adjuvant therapy in pancreatic cancer.
    J Surg Oncol, 95(7): 597-603. [Abstract] [Full-text]
82. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome.
    J Neurol Neurosurg Psychiatry, 78(7): 690-3. [Abstract] [Full-text]
83. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    Gynecol Oncol, 106(1): 16-22. [Abstract] [Full-text]
84. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Gynecol Oncol, 106(1): 160-3. [Abstract] [Full-text]
85. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.
    Gynecol Oncol, 106(1): 164-9. [Abstract] [Full-text]
86. Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes.
    Maturitas, 57(3): 315-24. [Abstract] [Full-text]
87. Life prevalence and determinants of hormone replacement therapy in women living in Porto, Portugal.
    Maturitas, 57(3): 226-32. [Abstract] [Full-text]
88. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
    Maturitas, 57(3): 239-46. [Abstract] [Full-text]
89. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
    J Clin Oncol, 25(18): 2580-5. [Abstract] [Full-text]
90. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
    J Clin Oncol, 25(18): 2567-72. [Abstract] [Full-text]
91. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
    J Clin Oncol, 25(18): 2540-5. [Abstract] [Full-text]
92. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
    J Clin Oncol, 25(18): 2522-7. [Abstract] [Full-text]
93. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
    J Clin Oncol, 25(18): 2509-15. [Abstract] [Full-text]
94. The art of prescribing. Monotherapy antidepressant: a thing of the past? Implications for the treatment of major depressive disorder.
    Perspect Psychiatr Care, 43(3): 142-5. [Abstract] [Full-text]
95. Time course of elevated ethanol intake in adolescent relative to adult rats under continuous, voluntary-access conditions.
    Alcohol Clin Exp Res, 31(7): 1159-68. [Abstract] [Full-text]
96. Utility of contrast enema for detecting anastomotic strictures after total proctocolectomy and ileal pouch-anal anastomosis.
    AJR Am J Roentgenol, 189(1): 25-9. [Abstract] [Full-text]
97. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.
    Clin Infect Dis, 45(2): 254-60. [Abstract] [Full-text]
98. Subclinical photodynamic therapy treatment modifies the brain microenvironment and promotes glioma growth.
    Glia, 55(10): 1053-60. [Abstract] [Full-text]
99. Estrogen therapy and coronary-artery calcification.
    N Engl J Med, 356(25): 2591-602. [Abstract] [Full-text]
100. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.
     J Neurosci, 27(25): 6701-11. [Abstract] [Full-text]
101. Sex hormones and the cardiovascular system: effects on arterial function in women.
     Clin Exp Pharmacol Physiol, 34(7): 672-6. [Abstract] [Full-text]
102. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs.
     Am Heart J, 154(1): 3-11. [Abstract] [Full-text]
103. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
     BMC Cancer, 7: 91. [Abstract] [Full-text]
104. Independent extended nurse prescribing for patients with skin conditions: a national questionnaire survey.
     J Clin Nurs, 16(7): 1247-55. [Abstract] [Full-text]
105. Supplementary nurse prescribing for patients with skin conditions: a national questionnaire survey.
     J Clin Nurs, 16(7): 1230-7. [Abstract] [Full-text]
106. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
     Exp Hematol, 35(7): 1074-82. [Abstract] [Full-text]
107. Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer.
     Cancer Causes Control, 18(7): 723-33. [Abstract] [Full-text]
108. Healthcare utilization of patients accessing an African national treatment program.
     BMC Health Serv Res, 7: 80. [Abstract] [Full-text]
109. Dispensing error rate after implementation of an automated pharmacy carousel system.
     Am J Health Syst Pharm, 64(13): 1427-31. [Abstract] [Full-text]
110. Effects of a pharmacist-led pediatrics medication safety team on medication-error reporting.
     Am J Health Syst Pharm, 64(13): 1422-6. [Abstract] [Full-text]
111. Debunking 7 myths that hamper the realization of randomized controlled trials on intra-arterial thrombolysis for acute ischemic stroke.
     Stroke, 38(7): 2191-5. [Abstract] [Full-text]
112. CT-NIHSS mismatch does not correlate with MRI diffusion-perfusion mismatch.
     Stroke, 38(7): 2079-84. [Abstract] [Full-text]
113. Sex disparity in the access of elderly patients to acute stroke care.
     Stroke, 38(7): 2123-6. [Abstract] [Full-text]
114. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke.
     Stroke, 38(7): 2173-5. [Abstract] [Full-text]
115. The Interventional Management of Stroke (IMS) II Study.
     Stroke, 38(7): 2127-35. [Abstract] [Full-text]
116. Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.
     Expert Opin Investig Drugs, 16(7): 1059-68. [Abstract] [Full-text]
117. Anticancer carrier-linked prodrugs in clinical trials.
     Expert Opin Investig Drugs, 16(7): 1037-58. [Abstract] [Full-text]
118. The utility of adding retrospective medication profiling to computerized provider order entry in an ambulatory care population.
     J Am Med Inform Assoc, 14(4): 424-31. [Abstract] [Full-text]
119. Randomized trial to improve prescribing safety during pregnancy.
     J Am Med Inform Assoc, 14(4): 440-50. [Abstract] [Full-text]
120. In vitro gene delivery to HepG2 cells using galactosylated 6-amino-6-deoxychitosan as a DNA carrier.
     Carbohydr Res, 342(11): 1427-33. [Abstract] [Full-text]
121. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy.
     Oncogene, 26(30): 4383-93. [Abstract] [Full-text]
122. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists.
     Dig Dis Sci, 52(8): 1798-805. [Abstract] [Full-text]
123. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
     BMC Ophthalmol, 7: 10. [Abstract] [Full-text]
124. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
     J Thorac Cardiovasc Surg, 134(1): 188-93. [Abstract] [Full-text]
125. Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery.
     J Thorac Cardiovasc Surg, 134(1): 59-64. [Abstract] [Full-text]
126. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model.
     Am J Epidemiol, 166(2): 219-27. [Abstract] [Full-text]
127. Raloxifene, tamoxifen and vascular tone.
     Clin Exp Pharmacol Physiol, 34(8): 809-13. [Abstract] [Full-text]
128. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
     Clin Infect Dis, 45(3): 381-90. [Abstract] [Full-text]
129. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
     Clin Infect Dis, 45(3): 370-6. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.